Detalles de la búsqueda
1.
Considerations for assessing the potential effects of antidiabetes drugs on cardiac ventricular repolarization: A report from the Cardiac Safety Research Consortium.
Am Heart J
; 170(1): 23-35, 2015 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-26093861
2.
Assessment of drug-induced increases in blood pressure during drug development: report from the Cardiac Safety Research Consortium.
Am Heart J
; 165(4): 477-88, 2013 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-23537963
3.
The evaluation and management of drug effects on cardiac conduction (PR and QRS intervals) in clinical development.
Am Heart J
; 165(4): 489-500, 2013 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-23537964
4.
Cardiac imaging approaches to evaluate drug-induced myocardial dysfunction.
Am Heart J
; 164(6): 846-55, 2012 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-23194484
5.
Days alive and out of hospital and the patient journey in patients with heart failure: Insights from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) program.
Am Heart J
; 162(5): 900-6, 2011 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-22093207
6.
Albuminuria in chronic heart failure: prevalence and prognostic importance.
Lancet
; 374(9689): 543-50, 2009 Aug 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-19683640
7.
Impact of hospitalization for acute coronary events on subsequent mortality in patients with chronic heart failure.
Eur Heart J
; 30(3): 338-45, 2009 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-19001475
8.
Feasibility of treating prehypertension with an angiotensin-receptor blocker.
N Engl J Med
; 354(16): 1685-97, 2006 Apr 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-16537662
9.
Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program.
Eur J Heart Fail
; 11(2): 170-7, 2009 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-19168515
10.
Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme.
Eur Heart J
; 29(24): 3022-8, 2008 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-18987098
11.
Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme.
Eur Heart J
; 29(21): 2641-50, 2008 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-18819960
12.
Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme.
Eur Heart J
; 29(11): 1377-85, 2008 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-18413309
13.
Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure.
Circulation
; 116(13): 1482-7, 2007 Sep 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-17724259
14.
Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program.
Circulation
; 115(24): 3111-20, 2007 Jun 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-17562950
15.
Body mass index and prognosis in patients with chronic heart failure: insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program.
Circulation
; 116(6): 627-36, 2007 Aug 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-17638930
16.
Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
Eur J Heart Fail
; 10(2): 157-63, 2008 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-18242128
17.
An evaluation of the effects of an angiotensin receptor blocker on health-related quality of life in patients with high-normal blood pressure (prehypertension) in the Trial of Preventing Hypertension (TROPHY).
J Clin Hypertens (Greenwich)
; 10(6): 436-42, 2008 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-18550933
18.
Renal function as a predictor of outcome in a broad spectrum of patients with heart failure.
Circulation
; 113(5): 671-8, 2006 Feb 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-16461840
19.
Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program.
Circulation
; 113(7): 986-94, 2006 Feb 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-16476847
20.
Prevalence and prognostic impact of bundle branch block in patients with heart failure: evidence from the CHARM programme.
Eur J Heart Fail
; 9(5): 510-7, 2007 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-17317308